Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Vanguard Value Index Fund ETF (VTV) Price & Performance

Adaptive Biotechnologies CorpTrade
Vanguard Value Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Vanguard Value Index Fund ETF — how do they compare? Adaptive Biotechnologies Corp trades at $24.97 (market cap $4.04B), while Vanguard Value Index Fund ETF trades at $226.1. Which is the better fit depends on your goals.

ADPTVTV
Market Cap
$4.04B
Sector
Health
52-Week High
$25.45$225.35
52-Week Low
$12.30$179.43
Enterprise Value
$4.10B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.

Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.

Vanguard Value Index Fund ETF

VTV trades at $225.71, up 0.31% with a bullish technical outlook from moving averages. The ETF focuses on large-cap value stocks and has gained attention for outperforming growth counterparts in 2026. Recent institutional activity shows mixed positioning, with some firms increasing stakes while others reduced exposure. A dividend of $1.08 is scheduled for June 2026, adding income appeal.

The value rotation narrative supports VTV's momentum, though RSI levels indicate potential near-term overbought conditions. Risks include sector concentration and market volatility. Analyst sentiment remains positive given the ETF's diversification and current market trends favoring value strategies over tech-heavy indexes.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Vanguard Value Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VTV